2. Academic Validation
  3. Identification of a new class of HBV capsid assembly modulator

Identification of a new class of HBV capsid assembly modulator

  • Bioorg Med Chem Lett. 2021 May 1:39:127848. doi: 10.1016/j.bmcl.2021.127848.
Scott D Kuduk 1,  Bart Stoops 2,  Richard Alexander 3,  Angela M Lam 4,  Christine Espiritu 4,  Robert Vogel 4,  Vincent Lau 4,  Klaus Klumpp 4,  Osvaldo A Flores 4,  George D Hartman 4
Affiliations

Affiliations

  • 1 Novira Therapeutics, a Janssen Pharmaceuticals Company, 1400 McKean Road, Spring House, PA 19477, United States. Electronic address: [email protected].
  • 2 Janssen Pharmaceutica, N. V. Turnhoutseweg 30, 2340 Beerse, Belgium.
  • 3 Janssen Research and Development, 1400 McKean Road, Spring House, PA 19477, United States.
  • 4 Novira Therapeutics, a Janssen Pharmaceuticals Company, 1400 McKean Road, Spring House, PA 19477, United States.
PMID: 33610748 DOI: 10.1016/j.bmcl.2021.127848
Abstract

The HBV core protein is a druggable target of interest due to the multiple essential functions in the HBV life cycle to enable chronic HBV Infection. The core protein oligomerizes to form the viral capsid, and modulation of the HBV capsid assembly has shown efficacy in clinical trials. Herein is described the identification and hit to lead SAR of a novel series of pyrazolo piperidine HBV capsid assembly modulators.

Keywords

Capsid; HBV; Modulator; Urea.

Figures